Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5b-20-epoxy-12a,4,7b,10b,13a-hexahydroxytax- 11-en-9-one 4-acetate 2-benzoate, anhydrous or trihydrate.
There are two types of Docetaxel products on the market.
Docetaxel, Trihydrate is a white to almost-white crystalline powder with an empirical formula of C43H53NO14• 3H2O, and a molecular weight of 861.9.
Docetaxel, Anhydrous is a white to almost-white microcrystalline powder with an empirical formula of C43H53NO14, and a molecular weight of 807.9.
Specification of Docetaxel, Anhydrous:
Shelf Life - 2 years.
Specification of Docetaxel, Trihydrate:
Shelf Life - 3 years.
Background and Applications
A drug developed by Aventis Pharmaceuticals (formerly Rhône-Poulenc Rorer Pharmaceuticals Inc. and Hoechst Marion Roussel, Inc.) for the treatment of certain types of cancer,
Taxotere is now approved in 90 countries to treat advanced breast cancer and 70 countries to treat patients with advanced non-small-cell lung cancer.
Taxotere is the first anticancer agent to show a
significantly higher response rate than Adriamycin® (doxorubicin), a very
active agent and widely used chemotherapy in the first-line treatment
Taxotere as a single agent was compared to mitomycin C
in combination with vinblastine and showed a one-year survival rate of 49
percent among breast cancer patients, compared to 33 percent for those
treated with the combination therapy. Fifty percent more patients treated
with Taxotere were alive one year after therapy, compared to those treated
with the combination. Median time to progression and time to treatment
failure were significantly longer for
Taxotere has been studied extensively in more than 200 clinical trials involving more than 85,000 patients worldwide. Approximately 10,000 breast cancer patients worldwide have been treated with Taxotere.
In one randomized Phase III multi-center study,
Taxotere showed a 50 percent better overall response rate compared to
patients treated with Adriamycin (45 percent for Taxotere vs. 30 percent
for Adriamycin). The overall response ate is the partial response rate (50
percent of greater reduction in
Patients in both Phase III trials were a poor prognostic group. In the study of Taxotere versus doxorubicin, three-quarters of all patients had disease that had spread to other internal organs, almost half had three or more organs showing evidence of disease and approximately half had received prior chemotherapy for metastatic disease. In the trial of Taxotere versus mitomycin C plus vinblastine, approximately half the patients had liver metastases, three-quarters had disease that had spread to other internal organs, and about one-third had received chemotherapy in both the adjuvant and metastatic setting.
LUNG CANCER - Non-Small-Cell
In a Phase III clinical study involving NSCLC patients whose disease had progressed on prior platinum-based chemotherapy, patients treated with Taxotere 75 mg/m2 plus best supportive care had a significantly higher one-year survival rate (37 percent) compared to patients who received best supportive care alone (12 percent).
In another study, NSCLC patients who had undergone
prior platinum-based chemotherapy had a higher one-year survival rate when
treated with Taxotere than with either Navelbine® (vinorelbine) or Ifex®
(ifosfamide), two other chemotherapy agents. Of the patients treated with
75 mg/m2 of Taxotere, 30 percent were alive at one year, as compared to 20
percent of those treated with vinorelbine or